A bloodspot assay has been developed using an antiserum raised against androstenedione-3-carboxymethyloxime-bovine serum albumin (AD-3CMO-BSA) conjugate and 125I-AD-3CMO-histamine tracer. The method has a detection limit of 0·6 nmol/L blood and a working range from 0·6 to 40 nmol/L blood. The betweenbatch precision ranged from 8-4% to 23·3%. Bloodspot androstenedione (AD) concentrations were measured in 50 neonates (26 male, 24 female) and in 95 children (54 male, 41 female) aged 6 months to 18 years. No sex difference in concentrations was found in neonates, in pre-pubertal children up to 8 years of age, in pubertal children (males 8-16 years, females 8-14 years) or post-puberty. Bloodspot AD concentrations ranged from < 0·6 to 2·7 nrnol/L in neonates, < 0·6 nmol/L in pre-pubertal children, 0,6-2,1 nrnol/L in pubertal children and < 0·6--4·6 nrnol/L post-puberty.
A bloodspot assay has been developed using an antiserum raised against androstenedione-3-carboxymethyloxime-bovine serum albumin (AD-3CMO-BSA) conjugate and 125I-AD-3CMO-histamine tracer. The method has a detection limit of 0·6 nmol/L blood and a working range from 0·6 to 40 nmol/L blood. The betweenbatch precision ranged from 8-4% to 23·3%. Bloodspot androstenedione (AD) concentrations were measured in 50 neonates (26 male, 24 female) and in 95 children (54 male, 41 female) aged 6 months to 18 years. No sex difference in concentrations was found in neonates, in pre-pubertal children up to 8 years of age, in pubertal children (males 8-16 years, females 8-14 years) or post-puberty. Bloodspot AD concentrations ranged from < 0·6 to 2·7 nrnol/L in neonates, < 0·6 nmol/L in pre-pubertal children, 0,6-2,1 nrnol/L in pubertal children and < 0·6--4·6 nrnol/L post-puberty.
Daytime bloodspot profiles in 10 children on replacement therapy for congenital adrenal hyperplasia generally showed good correlation between 171X-hydroxyprogesterone and AD concentrations (r=0'928, P<O·OOI). Bloodspot AD profiles have advantages over 171X-hydroxyprogesterone profiles for the assessment of the adequacy of glucocorticoid replacement therapy.
Congenital adrenal hyperplasia (CAH) is the commonest adrenal disorder in childhood and infancy. Over 90% of cases are due to deficiency of adrenal 21-hydroxylase enzyme (EC 1.1.1.151); this is inherited as an autosomal recessive trait with an incidence within the range of I in 5000 to I in 20000 in Western Europe' 4. In addition to the inadequate cortisol synthesis and excessive production of precursor steroids and adrenal androgens, in approximately 50-80% of patients with 21-hydroxylase deficiency the deficiency of the enzyme in the zona glomerulosa is sufficiently severe to cause aldosterone deficiency and salt-wasting.
Plasma 171X-hydroxyprogesterone (17-0HP) measurements have gained widespread acceptance for the diagnosis of 21-hydroxylase deficiency.' More recently, bloodspot assay methods have been introduced for diagnosis of the disorder, and bloodspot 17-0HP daytime profiles can be used (in addition to assessment of growth Correspondence: Dr P J Wood, Regional Endocrine Unit, Duthie Building,Southampton General Hospital, Tremona Road, Southampton S09 4XY, UK. 262 velocity and bone age) to assess the efficacy of glucocorticoid replacement therapy.v" Plasma or bloodspot 17-0HP measurements for the monitoring of replacement therapy suffer from the potential drawbacks of a large diurnal rhythm," which is exaggerated in untreated CAH, and of short-term fluctuations with individual steroid replacement doses." In addition, they do not provide a direct measurement of adrenal androgen production.
Since the main aim of glucocorticoid replacement is to suppress excessive adrenal androgen production, several groups have recommended the monitoring of androstenedione (AD) or testosterone.!"" The value of testosterone estimations is limited by the fact that they cannot be used to monitor boys after puberty. Plasma AD levels, however, can be used to monitor control of CAH in patients of all ages 10 . 12 and have been shown to have less diurnal rhythm and to be less influenced by individual steroid doses than are plasma 17-0HP levels."
We have developed a bloodspot AD assay, since this should combine the advantages of AD measurement with convenience of a home- 0·8 mg/ml, bovine gammaglobulin). After vortex-mixing, tubes were left to stand at 4°C for 15 min before centrifugation, aspiration of supernatants and counting of the pellets. A precision profile for the method, calculated from the duplicate results from 15 consecutive batches, is illustrated in Fig. I . The detection limit for the assay, calculated by the method of Ekins, 14 was 0·6 nmol/L blood. Antiserum specificity, assessed from cross-reactivity of 18 steroids in the assay system, is detailed in Table 1 .
Methods monitoring method. References ranges for bloodspot AD measurements in normal children have been established and the potential of the assay for home-monitoring of steroid replacement therapy in children with CAH has been assessed.
PREPARATION OF AD-FREE BLOOD AND
BLOODSPOT STANDARDS AD-free blood, used to make bloodspot standards for the assay, was prepared by charcoaltreating plasma separated from heparinised whole blood. The plasma was stirred with charcoal (Norit GSX, 20 g/100 mL plasma) for 24 h at 4°C. Charcoal was sedimented by centrifugation at 3000 rpm for 15 min (MSE bench top centrifuge; MSE Ltd, Loughborough, Leicester, UK) and then at 2500 rpm for I h (MSE HS 18 centrifuge). Red cells were resuspended and washed in saline (9 giL) and separated by centrifugation at 3000 rpm for 15 min. Plasma and red cells were then re-mixed in proportions 55: 45. AD standards were prepared in this matrix at levels of 0·6 to 40 nmol/L blood; bloodspots were made for each standard level, left to dry overnight at room temperature and then stored at -20°C. Steroid % Cross-reaction"
• Calculated from steroid concentrations giving 50% displacement of tracer bound in zero standard tubes.
PLASMA AD ASSAY
The plasma AD assay, used to compare bloodspot and plasma results on the same blood samples, utilised 10 JiL test plasma, or, for the standards, 10 JiL AD-free plasma. Assay buffer BLOODS POT ASSAY Duplicate 6 mm diameter bloodspots were punched from standards, controls or tests, and each was eluted with 200 JiL assay buffer (50 rnmol/L Tris pH 7,5, containing bovine serum albumin (BSA) 5 g/L, and sodium azide I g/L) in screw top glass tubes (Labco, Marlow, Bucks, UK) for 30 min at 37"C in a shaking water bath. A mixture of n-hexane and ether (4: I, v[v; 2 mL per tube) was then added and tubes were vortexmixed for 4 min. After centrifugation at 2500 rpm for 10 min, aqueous layers were frozen in a bath of solid C0 2/methylated spirits. Solvent layers were then decanted into 10 x 76 mm glass tubes and the solvent evaporated under a stream of nitrogen at 37°C. AD levels were determined in the dried extracts by the addition of 100 JiL of 125I-AD-3CMO histamine tracer, prepared by the method of Hunter et al." (10 nCi per tube in assay buffer). Following the addition of 100 JiL of rabbit anti-AD-3CMO-BSA (Glasgow Royal Infirmary Code B) at a dilution of 1 in 32000, tubes were incubated overnight at 4°C. Bound radioactivity was separated by the addition of 1·0 mL cold, freshly prepared polyethylene glycol/gamrnaglobulin reagent (PEG 6000, 160 giL, containing (200 J.lL) was added to the test samples, and 100 J.lL buffer together with 100 J.lL of standards in assay buffer (0-5 nmol/L) were added to the standard tubes prior to extraction with hexane/ ether and analysis by radioimmunoassay, using the same protocol as that for the bloodspot method.
COMPARISON OF PLASMA AND BLOODSPOT ASSAYS Plasma and bloodspot measurements on 9 specimens with bloodspot AD levels ranging from 0·7 to 4·6 nrnol/L (plasma AD range 2,9-10,9 nmol/ L) showed good correlation (r=0'949) with a 'Deming' regression equation of: bloodspot AD=0·46 x plasma AD-0·61.
STABILITIES OF SAMPLES
A stability study, in which replicate bloodspots were kept at room temperature and 4°C for varying time periods before freezing at -20°C, showed that results remained stable for at least 3 months at both room temperature and 4°C.
CONTROL SUBJECTS
Ninety-five children (54 male, and 41 female) aged between 6 months and 18 years, who were attending Southampton General Hospital for routine blood tests, had an extra I mL of blood taken into heparin. Bloodspots were made from 5 4 each sample, dried overnight at room temperature and then stored at -70°C until analysed. Children were divided into groups dependent on age and sex: pre-pubertal (age 0,1-7,9 years); pubertal (females aged 8-13'9 years; males aged 8-15'9 years), post-pubertal (females over 14 years; males over 16 years), following the protocol used by Lee et al. ' ?
For the neonatal reference range, 50 neonatal bloodspots, taken for phenylketonuria screening 6-8 days after delivery, were stored for one week at room temperature and then assayed for androstenedione.
PATIENTS
Ten patients (4 male, 6 female, aged 2-19 years) with CAH due to 2 I-hydroxylase deficiency were studied. All were on replacement therapy, and all but two were salt-losers. Bloodspots (6 for each collection time) were collected onto filter paper (Grade 2992, Anderman & Co Ltd, Kingston-on-Thames, Surrey, UK) at 8 a.m., 12 noon, 6 p.m. and II p.m. using an Autolet (Owen Mumford Ltd, Woodstock, Oxford, UK) and stored at -20°C prior to analysis for AD and 17-0HP.
Results
Bloodspot AD concentrations in normal infants • -l 3 :::: and children are illustrated in Fig. 2 . There was no significant difference between boys and girls in any of the age groups (P> 0·05; Mann-Whitney U test) and therefore data were combined for calculation of reference ranges. All pre-pubertal children and the majority of pubertal children had concentrations below the detection limit of the method « 0·6 nmol(L). Higher concentration were seen in neonates and post-puberty. Absolute ranges for bloodspot AD for the four groups were <0'6-2·7 nmol(L (neonates), < 0·6 nmol(L (pre-pubertal), < 0'6-2·1 nmol(L (pubertal) and < 0·6-4,6 nmol(L (post-pubertal).
Of the children with CAH who were studied, five showed bloodspot AD concentration of less than 0·6 nmol(L at all sampling times, with 17-OHP concentrations correspondingly low. Results for two other patients are presented to illustrate different patterns of AD and 17-0HP profiles. Fig. 3 shows the bloodspot AD and 17-0HP profiles in the first patient, a boy aged 9 with the non-salt-losing form of 21-hydroxylase deficiency. The 8 a.m. 17-0HP concentration was moderately raised at 80 nmol/l whilst the AD concentrations remained normal over the profile period. Fig. 4 illustrates results for a boy aged 12, with the salt-losing form of CAH, who was clinically out of control due to non-compliance. Both 17-0HP and AD concentrations were very high for the 8 a.m. sample, AD concentrations remained elevated throughout the profile period, whilst 17-0HP concentrations fell to within the references range later in the day.
Discussion
The bloodspot AD assay can be completed within approximately 3 h 'hands-on' time (20 h total analysis time) and has sufficient sensitivity (0'6 nmol/L) to permit detection of AD concentrations at or near the upper limit of normal. Between-batch precision, although not as good as that for most plasma steroid assays, is comparable to those found for other elution/extraction assays of bloodspot 17-0Hp4·7 and is adequate for assessment of control.
Reference ranges in children, determined with the bloodspot AD assay, correlate well with serum AD ranges in children published by other groups." II Korth-Schutz et al.,10 for example, found mean serum AD concentration of 0·44 nrnol/L (males) and 0·64 nmol/L (females) in children at Tanner stage I of puberty, approximately 2 nrnol/L for Tanner stages II and III, and 4-5 nmol/L for stage IV.
One problem with the use of bloodspot 17-OHP for assessment of control is that morning levels are moderately raised when control is good: complete suppression of 17-0HP throughout the day suggests overtreatment. It is difficult to assess the upper limit for an 8 a.m. 17-0HP concentration which is still compatible with a reasonable replacement regimen, but in our experience 8 a.m. concentrations up to 70 or 80 nrnol/L may still indicate adequate replacement. The profiles of the 9-year-old child (Fig. 3) illustrate this point. The child was considered to be on adequate replacement therapy and had a normal growth velocity. Although the 8 a.m. bloodspot 17-0HP concentration was moderately raised at 82 nmol/L, AD measurements were within the reference range at all times, giving reassurance that replacement steroid doses were correct. In the case of the 12year-old who was judged to be out of control on clinical assessment, bloodspot 17-0HP concen-trations were very high (360 nrnol/L) at 8 a.m. but fell to within the reference range at the other three sampling times (Fig. 4) . Although bloodspot AD concentrations also showed a fall during the day, they remained above normal. This evidence of lack of control could be missed with 17-0HP measurements, but not with AD measurements, if samples had been taken only later in the day.
One potential drawback of the bloodspot AD assay is that the detection limit is not sufficiently low to identify suppressed concentration associated with over-treatment. This is possible with the bloodspot 17-0HP method, and at present maximum information is gained from measurement of both AD and 17-0HP in bloodspots.
We conclude that measurement of bloodspot AD concentrations gives valuable information on adequacy of corticosteroid replacement therapy for CAH. Preliminary results indicate that this measurement gives a more reliable indication of the efficacy of replacement therapy for CAH than 17-0HP. Work is in progress to assess the relative merits of bloodspot 17-0HP and AD profiles for this purpose.
